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Albuminuria reduction: The Holy 
Grail for Kidney Protection
KR Tuttle1,2
Increased urinary excretion of albumin or total protein has become 
firmly established as a risk predictor for progression of chronic kidney 
disease. Observational analyses have raised a strong hypothesis that 
albuminuria reduction should be a clinical treatment target. Bakris 
et al. report further exploration of albuminuria-lowering capabilities 
of intensified renin–angiotensin system inhibition in a randomized 
clinical trial that included patients at high cardiovascular risk, most of 
whom appeared to have diabetic kidney disease.
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Holy Grail: a distant, ultimate goal
Increased urinary excretion of albumin 
or total protein has become ﬁrmly estab-
lished as a risk predictor for progression of 
chronic kidney disease (CKD). Reduction 
of albuminuria/proteinuria (referred to as 
‘albuminuria’ from here forward) has been 
associated with decreased risk of major 
clinical events (death, end-stage renal 
disease, or 50% loss of kidney function) 
in both diabetic and nondiabetic forms 
of CKD.1–3 The most commonly studied 
treatments for albuminuria reduction are 
the renin–angiotensin system inhibitors, 
angiotensin-converting enzyme inhibitor, 
and angiotensin receptor blockers.
Observational analyses from studies of 
renin–angiotensin system inhibitors have 
been performed to examine relationships 
between albuminuria change and clinical 
events. The ﬁrst of these analyses from 
a large randomized trial of angiotensin 
receptor blockade in diabetic kidney dis-
ease characterized by macroalbuminuria 
showed that reduction in albuminuria at 
6 months strongly predicted improved 
kidney and cardiovascular outcomes, 
whereas an increase in albuminuria pre-
dicted the opposite.1,4 Another more 
recent analysis from the same study 
suggests that predictive ability of albu-
minuria change for kidney outcomes can 
largely be dissociated from blood pres-
sure changes in diabetic kidney disease.5 
In addition, observational analyses from 
clinical trials of renin–angiotensin sys-
tem inhibition in hypertensive African 
Americans with CKD and hypertensive 
patients with left ventricular hypertrophy 
have also shown relationships between 
albuminuria change, or achieved level of 
albuminuria, during the trials and kid-
ney and cardiovascular outcomes.3,6 In 
the latter two studies, most patients had 
microalbuminuria, which potentially 
extends the spectrum of albuminuria 
amenable to treatment. This emerging 
body of data has led to the suggestion 
that treatment with renin–angiotensin 
system inhibitors should target reduction 
of albuminuria as well as blood pressure. 
In other words, increasing the dosage or 
intensity of treatment with renin–angi-
otensin system inhibition to reduce 
albuminuria should be considered even 
if blood pressure is at goal.
Either prespeciﬁed secondary or post 
hoc analyses of clinical trials have raised 
a strong hypothesis that albuminuria 
reduction should be a clinical treatment 
target. In further support of the hypoth-
esis, experimental studies have shown 
biologic rationale for the clinical obser-
vations. Urinary albumin appears to be 
proinﬂammatory to the tubulointersti-
tium in particular and could contribute 
to progressive kidney damage and loss of 
function.7 However, caution is in order 
before this hypothesis, or any other, is 
accepted as fact. First, although scien-
tiﬁc inquiry begins with a hypothesis, 
the conclusion should not be presumed 
before it has been rigorously tested. Sec-
ond, alternate hypotheses should also 
be considered. For example, albuminu-
ria may be a marker of patient respon-
siveness to therapy rather than a causal 
mechanism for kidney and cardiovascu-
lar disease. Third, obsession with a single 
risk factor or marker may lead to missed 
opportunities to ﬁnd therapies that work 
through diﬀerent pathways.
Bakris et al.8 (this issue) now report 
further exploration of albuminuria-
lowering capabilities of intensified 
renin–angiotensin system inhibition in 
a randomized clinical trial that included 
patients at high cardiovascular risk, most 
of whom appeared to have diabetic kid-
ney disease: the Irbesartan in the Man-
agement of PROteinuric patients at high 
risk for Vascular Events (IMPROVE) 
trial.8 Renin–angiotensin system inhi-
bition was intensiﬁed by dual blockade, 
ramipril plus irbesartan, in comparison 
with treatment with the angiotensin-
converting enzyme inhibitor alone. 
Because of unanticipated and substantial 
variability in albuminuria, particularly 
among the majority of participants who 
had microalbuminuria (70%), the study 
was underpowered for the primary end 
point of change in albuminuria over 
20 weeks. However, despite signiﬁcantly 
lower systolic and diastolic blood pres-
sures in the dual-blockade group, the 
degree of albuminuria reduction was no 
diﬀerent from that in the group treated 
with ramipril alone. Indeed, both groups 
had considerable decreases in albuminuria 
that approached 50%. When analyzed 
by quantity of albuminuria, those with 
macroalbuminuria (≥200 µg/min) 
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tended to have a greater response to dual 
blockade, but the between-group dif-
ference was not statistically signiﬁcant. 
Albuminuria responsiveness to dual 
blockade versus ramipril alone also did 
not diﬀer by diabetes status. Besides low 
power, the IMPROVE study was limited 
by short duration and lack of additional 
kidney outcome measures such as esti-
mates of glomerular filtration rate or 
other markers of damage.
The IMPROVE results stand in con-
trast to a prior short-term study of dual 
renin–angiotensin system blockade com-
pared with single-agent therapy in dia-
betic patients with microalbuminuria, 
the Candesartan and Lisinopril Micro-
albuminuria (CALM) study. In CALM, 
albuminuria reduction was enhanced by 
the combination of angiotensin-convert-
ing enzyme inhibition and angiotensin 
receptor blockade compared with either 
agent alone.9 The CALM study enrolled 
patients with a narrower range of albu-
minuria, which may have reduced vari-
ability and provided a clearer result. On 
the other hand, publication bias for posi-
tive results is also a legitimate concern. 
Initial impressions may not remain as 
optimistic as ﬁrst reported after more 
studies are completed. Irrespective of 
whether albuminuria is a disease mech-
anism or marker, it has a fairly reliable 
association with clinical outcomes. If 
the IMPROVE results are viewed from 
the perspective of greater versus lesser 
blood pressure lowering, they appear 
consistent with some larger long-term 
studies of hypertensive patients with 
early-stage CKD or non-CKD, wherein 
clinical events, loss of kidney function, 
or albuminuria did not diﬀer by a higher 
or lower blood pressure goal.10,11
The IMPROVE study leads to still 
more questions in the context of current 
understanding of increased albuminuria 
and its clinical correlates. Importantly, 
studies with albuminuria reduction as 
the speciﬁc treatment target are needed 
to validate the recommendation that 
such treatments be titrated to urinary 
albumin. Studies should also carefully 
specify the population and outcomes of 
interest. For example, do renin–angi-
otensin system inhibitors reduce kidney 
events in patients with diabetic kidney 
disease when dose is titrated to targets 
for albuminuria and blood pressure? 
Does targeting albuminuria reduction 
in hypertensive patients reduce car-
diovascular events? What is the proper 
albuminuria target? Can achieving 
the albuminuria target be sustained? 
Do treatments to reduce albuminuria 
other than renin–angiotensin inhibition 
— for example, novel agents for CKD 
or intensive glycemic control in diabetes 
— have the same or similar relationships 
to clinical outcomes? Do relationships 
between albuminuria change and clini-
cal outcome vary by cause of CKD? In 
order to improve on conﬁdence in sur-
rogates of CKD, even better biomarkers 
than albuminuria are urgently needed. 
This is an area of active investigation 
that spans a wide range from new mark-
ers of kidney function to cytokines, 
ﬁbrosis molecules, and novel indicators 
of kidney damage and disease identiﬁed 
by rapidly moving scientiﬁc advances in 
genomics and proteomics.
The existing state of knowledge has led 
to a strong hypothesis that albuminuria 
reduction may be an important clini-
cal treatment target for various disease 
states. However, we should not presume 
the answers before the questions have 
been properly addressed by thorough 
scientiﬁc inquiry. Hypotheses, no matter 
how well founded, are not yet conﬁrmed 
facts. We must continue to ask legiti-
mate questions in order to move from 
a state of hypothesis to one of clinical 
evidence in the quest for the Holy Grail 
of optimal approaches to preventing and 
treating CKD.
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